Neuren Pharmaceuticals (ASX:NEU) sats it has received approval from the US FDA to proceed with the Phase 2 trial of NNZ-2591 in Angelman syndrome. …
Approval for Neuren Pharmaceuticals' Phase 2 trial in Angelman syndrome
March 1, 2022 Australian Biotech
Latest Video
New Stories
-
What is it with this organisation's obsession with pharmacy and Europe?
July 13, 2026 - - Latest News -
Mesoblast reports strong cell therapy revenue as first year as uptake grows
July 13, 2026 - - Latest News -
The inevitability of disappointment over a reform process that has devolved into word games
July 12, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep 23
July 10, 2026 - - Podcast -
Disruption is the overdue remedy and how this debate can revitalise the PBS
July 10, 2026 - - Latest News -
Melbourne study links higher tumour radiation dose to longer progression-free survival
July 10, 2026 - - Latest News -
Older Australians are underestimating their personal risk from RSV
July 10, 2026 - - Latest News